Original language | English (US) |
---|---|
Pages (from-to) | E72-E75 |
Journal | Haematologica |
Volume | 105 |
Issue number | 2 |
DOIs | |
State | Published - Jan 31 2020 |
ASJC Scopus subject areas
- Hematology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Variable global distribution of cell-of-origin from the ROBUST phase III study in diffuse large B-cell lymphoma. / Nowakowski, Grzegorz S.; Chiappella, Annalisa; Witzig, Thomas E.; Scott, David W.; Spina, Michele; Gascoyne, Randy D.; Zhang, Lei; Russo, Jacqueline; Kang, Janet; Zhang, Jingshan; Xu, Yingyong; Vitolo, Umberto.
In: Haematologica, Vol. 105, No. 2, 31.01.2020, p. E72-E75.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Variable global distribution of cell-of-origin from the ROBUST phase III study in diffuse large B-cell lymphoma
AU - Nowakowski, Grzegorz S.
AU - Chiappella, Annalisa
AU - Witzig, Thomas E.
AU - Scott, David W.
AU - Spina, Michele
AU - Gascoyne, Randy D.
AU - Zhang, Lei
AU - Russo, Jacqueline
AU - Kang, Janet
AU - Zhang, Jingshan
AU - Xu, Yingyong
AU - Vitolo, Umberto
N1 - Funding Information: 1Division of Hematology, Mayo Clinic, Rochester, MN, USA; 2Division of Hematology, Città della Salute e della Scienza Hospital and University, Torino, Italy; 3Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada; 4Division of Medical Oncology A, National Cancer Institute, Aviano, Italy and 5Celgene Corporation, Summit, NJ; USA Acknowledgments: we thank all of the co-investigators on the ROBUST clinical study; patients, families, and caregivers who are participating in the study; and support from Celgene Corporation for sponsoring the study. This work was supported by Celgene Corporation, Summit, NJ, USA and is a joint scientific collaboration Funding Information: among Fondazione Italiana Linfomi, Mayo Clinic, and Celgene. Editorial support was provided by Julie Kern, PhD, CMPP of Bio Connections LLC and funded by Celgene Corporation. The authors directed development of the manuscript and are fully responsible for all content and editorial decisions.
PY - 2020/1/31
Y1 - 2020/1/31
UR - http://www.scopus.com/inward/record.url?scp=85078815823&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078815823&partnerID=8YFLogxK
U2 - 10.3324/haematol.2019.220475
DO - 10.3324/haematol.2019.220475
M3 - Letter
C2 - 31221781
AN - SCOPUS:85078815823
VL - 105
SP - E72-E75
JO - Haematologica
JF - Haematologica
SN - 0390-6078
IS - 2
ER -